Alzheimer's disease
- PMID: 17226739
- DOI: 10.1055/s-2006-956753
Alzheimer's disease
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Currently, 4.5 million individuals in the United States are estimated to have AD, and that number is projected to increase to at least 14 million by the year 2050. AD is a major cause of disability and mortality, and its impact on health care costs, including direct and indirect medical and social service costs, is estimated to be greater than $100 billion per year. AD typically presents with an insidious decline in memory that progresses to affect language, visuospatial perception, calculations, and executive functioning. Behavioral and psychiatric symptoms are also frequent in AD. Diagnosis is determined clinically, as there is currently no laboratory test to confirm AD in life. The neuropathologic hallmarks of AD are neuritic plaques and neurofibrillary tangles. Currently available medical therapies have demonstrated modest benefits but likely do not alter disease progression. Caregivers play a large role in managing the patient and should be encouraged to seek out adult day care centers, home health services, respite care, and additional social support.
Similar articles
-
Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker.Neurobiol Aging. 2010 Jun;31(6):889-900. doi: 10.1016/j.neurobiolaging.2008.07.010. Epub 2008 Aug 28. Neurobiol Aging. 2010. PMID: 18760507
-
Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?Neurobiol Aging. 2007 Oct;28(10):1465-80. doi: 10.1016/j.neurobiolaging.2006.06.021. Epub 2006 Jul 31. Neurobiol Aging. 2007. PMID: 16876913 Review.
-
Diagnosis and management of Alzheimer's disease--an update.Med J Malaysia. 1999 Dec;54(4):541-9; quiz 550. Med J Malaysia. 1999. PMID: 11072482 Review.
-
Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease.Brain Res Rev. 2006 Aug;51(2):176-211. doi: 10.1016/j.brainresrev.2005.11.003. Epub 2006 Jan 18. Brain Res Rev. 2006. PMID: 16413610 Review.
-
Practical treatment strategies for patients with Alzheimer's disease.J Fam Pract. 2007 Dec;56(12 Suppl New):S17-23. J Fam Pract. 2007. PMID: 18664338 Review.
Cited by
-
Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies.Curr Pharm Des. 2016;22(26):4063-8. doi: 10.2174/1381612822666160518142110. Curr Pharm Des. 2016. PMID: 27189599 Free PMC article. Review.
-
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation.J Neurosci. 2010 Feb 17;30(7):2636-49. doi: 10.1523/JNEUROSCI.4456-09.2010. J Neurosci. 2010. PMID: 20164348 Free PMC article.
-
Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.Arch Neurol. 2011 Nov;68(11):1461-6. doi: 10.1001/archneurol.2011.535. Arch Neurol. 2011. PMID: 22084131 Free PMC article.
-
Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs. 2011 Oct 22;71(15):2031-65. doi: 10.2165/11595870-000000000-00000. Drugs. 2011. PMID: 21985169
-
Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease.Curr Alzheimer Res. 2015;12(4):335-49. doi: 10.2174/1567205012666150325182702. Curr Alzheimer Res. 2015. PMID: 25817254 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical